Cabozantinib in the CABINET Trial: NET Results - Yennifer Chan, MD - ESMO 2023

By. Yennifer Chan, MD

      Lisa Yen, MD

Courtesy: LACNETS

Date. 11/09/2023

Cabozantinib in the CABINET Trial: NET Results 

Lisa Yen, MD, the Director of Programs and Outreach at ESMO 2023 in Madrid, is alongside Dr. Jennifer Chan, the Principal Investigator of the Alliance Phase Three Study. This study, known as the Cabinet Study, explores Cabozantinib's efficacy compared to a placebo in Advanced Neuroendocrine Tumors after prior therapy. Dr. Chan recently revealed the trial's outcomes, demonstrating the effectiveness of Cabozantinib in both cohorts of patients. The results showed an improvement in progression-free survival for those receiving Cabozantinib compared to the placebo group, with no new safety concerns. The observed side effects aligned with Cabozantinib's known safety profile.

The trial included two patient cohorts: one with extra-pancreatic NETs and the other with pancreatic NETs. About 20% of the extra-pancreatic NET patients had lung neuroendocrine tumors, while more patients had GI neuroendocrine tumors, and some had tumors of unknown primary origin.

Most patients across both cohorts had grade one or two diseases, with a small number presenting higher-grade diseases. All patients had well or moderately differentiated neuroendocrine tumors.

The data revealed encouraging outcomes, suggesting that cabozantinib holds significant promise in managing NET, expanding the arsenal of viable treatments for patients facing these challenging conditions. This potential effectiveness extends hope to the NET patient community, raising the prospect of another FDA-approved oral medication becoming accessible in the foreseeable future. This development is particularly significant given the limited therapeutic options available for NET patients, especially for those with advanced or metastatic forms of the disease.

The CABINET trial findings not only highlight the potential of cabozantinib as an effective therapeutic avenue for NET but also hint at its applicability across different stages of the disease. The introduction of another FDA-approved oral treatment could revolutionize the landscape of care for NET patients, offering renewed optimism and prospects for enhanced quality of life and extended survival rates.

The news of these promising results from the CABINET trial brings a sense of anticipation and optimism within the medical community, particularly among healthcare professionals specializing in oncology and, most significantly, among individuals battling NET. It signifies a potential breakthrough in addressing the unmet medical needs of NET patients, offering a ray of hope for improved treatment outcomes and potentially transforming the standard of care in the management of these complex and challenging conditions.

Dr. Chan expressed excitement about these results, seeing it as a potential addition to the treatment options available for neuroendocrine tumor patients, particularly for those who have exhausted known effective therapies. The trial, active since 2018, recently concluded with its outcomes announced in July of this year. 

Cabozantinib in the CABINET Trial: NET Results - Yennifer Chan, MD - ESMO 2023

Jennifer Chan, MD, from the Dana Farber Cancer Institute, recently presented groundbreaking findings from the CABINET trial involving cabozantinib (marketed as CABOMETYX®). The trial specifically focused on its efficacy in treating advanced pancreatic neuroendocrine tumors (NET)